Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Patients with hepatocellular carcinoma (HCC) have two diseases in one organ: firstly, the underlying liver disease and, secondly, the HCC tumour. Both liver diseases cause a significant burden for the patient and may impact associated treatment. Together with partners, Roche aims to stop the progression of chronic liver disease and, one day, even cure HCC with interventions across detection, prevention and treatment. By rethinking the disease from every possible angle and developing integrated solutions, this new era of partnership and innovation can improve the lives of millions of people around the world.
As part of the ILCA 2020 virtual programme, Roche are pleased to present their sponsored industry symposium on Friday 11 September: “How could treatment practice change with cancer immunotherapy combinations in patients with HCC?”
In this symposium, an esteemed panel will provide an overview of the evolving treatment landscape for HCC, review the most recent phase III data for cancer immunotherapy combinations in patients with unresectable HCC and, crucially, provide expert insights and guidance on how their safety profiles should be navigated.